Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 6
2023 8
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Targeting TEAD-ious resistance.
Ott CA, Aplin AE. Ott CA, et al. Trends Cancer. 2023 Oct;9(10):780-781. doi: 10.1016/j.trecan.2023.07.016. Epub 2023 Aug 3. Trends Cancer. 2023. PMID: 37543514 Free PMC article.
Packing a Punch against PD-L1.
Capparelli C, Aplin AE. Capparelli C, et al. Cancer Discov. 2022 Jun 2;12(6):1413-1415. doi: 10.1158/2159-8290.CD-22-0301. Cancer Discov. 2022. PMID: 35652219
High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
Arang N, Lubrano S, Ceribelli M, Rigiracciolo DC, Saddawi-Konefka R, Faraji F, Ramirez SI, Kim D, Tosto FA, Stevenson E, Zhou Y, Wang Z, Bogomolovas J, Molinolo AA, Swaney DL, Krogan NJ, Yang J, Coma S, Pachter JA, Aplin AE, Alessi DR, Thomas CJ, Gutkind JS. Arang N, et al. Cell Rep Med. 2023 Nov 21;4(11):101244. doi: 10.1016/j.xcrm.2023.101244. Epub 2023 Oct 18. Cell Rep Med. 2023. PMID: 37858338 Free PMC article.
The future of targeted kinase inhibitors in melanoma.
Caksa S, Baqai U, Aplin AE. Caksa S, et al. Pharmacol Ther. 2022 Nov;239:108200. doi: 10.1016/j.pharmthera.2022.108200. Epub 2022 May 2. Pharmacol Ther. 2022. PMID: 35513054 Free PMC article. Review.
YAP-Driven Malignant Reprogramming of Epithelial Stem Cells at Single Cell Resolution.
Gutkind JS, Faraji F, Ramirez S, Clubb L, Sato K, Quiroz PA, Galloway W, Mikulski Z, Hoang T, Medetgul-Ernar K, Marangoni P, Jones K, Officer A, Molinolo A, Kim K, Sakaguchi K, Califano J, Smith Q, Klein O, Tamayo P. Gutkind JS, et al. Res Sq [Preprint]. 2023 Oct 27:rs.3.rs-3426301. doi: 10.21203/rs.3.rs-3426301/v1. Res Sq. 2023. PMID: 37961717 Free PMC article. Preprint.
Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth.
Han A, Mukha D, Chua V, Purwin TJ, Tiago M, Modasia B, Baqai U, Aumiller JL, Bechtel N, Hunter E, Danielson M, Terai M, Wedegaertner PB, Sato T, Landreville S, Davies MA, Kurtenbach S, Harbour JW, Schug ZT, Aplin AE. Han A, et al. Cancers (Basel). 2023 Jun 30;15(13):3451. doi: 10.3390/cancers15133451. Cancers (Basel). 2023. PMID: 37444561 Free PMC article.
Catalytic site mutations confer multiple states of G protein activation.
Hewitt N, Ma N, Arang N, Martin SA, Prakash A, DiBerto JF, Knight KM, Ghosh S, Olsen RHJ, Roth BL, Gutkind JS, Vaidehi N, Campbell SL, Dohlman HG. Hewitt N, et al. Sci Signal. 2023 Feb 14;16(772):eabq7842. doi: 10.1126/scisignal.abq7842. Epub 2023 Feb 14. Sci Signal. 2023. PMID: 36787384 Free PMC article.
15 results